Lon­don list­ed PureTech Health joins forces with ninth big phar­ma part­ner — Boehringer In­gel­heim

PureTech Health — which is de­vel­op­ing ther­a­peu­tics to tack­le dys­func­tions in the brain-im­mune-gut ax­is — is adding an­oth­er big bio­phar­ma­ceu­ti­cal com­pa­ny, Ger­many’s Boehringer In­gel­heim, to its rich ros­ter of part­ners with deep pock­ets.

The re­search col­lab­o­ra­tion al­lows Boehringer ac­cess to PureTech’s lym­phat­ic tar­get­ing tech­nol­o­gy for im­mune mod­u­la­tion. In re­turn, PureTech is el­i­gi­ble to re­ceive up to $26 mil­lion, in­clud­ing up­front pay­ments, re­search sup­port, and pre­clin­i­cal mile­stones, as well as an­oth­er $200 mil­lion in de­vel­op­ment and sales mile­stones, in ad­di­tion to roy­al­ties on prod­uct sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER